hey,
looks like we are getting a bit of damage control...finally. however, the problem i see with this press release is that they have yet to find a replacement for the San Diego clinic. i still can't believe that asshole defected. what miserable timing. anyway, hopefully they make good on their promise to begin human trials for famoxin in 4Q.
<<<Announces Strong Consolidation Of Its Metabolism Program Through New Key Hirings
PARIS, March 28 /PRNewswire/ -- Genset (Nasdaq: GENXY - news; Nouveau Marche: GENSET) today announced that Denis Ravel, Ph.D., former head of the Metabolism Department of the French pharmaceutical company Servier, has joined the Company as Director of Pharmaceutical Development in Genset's Paris offices.
Andre Pernet, president and chief executive officer of Genset, commented, ``Dr. Ravel brings excellent qualifications and more than 17 years of experience in the field of metabolism. In particular, he was instrumental in the development of several new anti-diabetic agents while at Servier. Dr. Ravel is taking command of the Famoxin development program, which remains on track.''
Genset has taken steps to ensure the continued success of the metabolic research group in San Diego through additional hirings and more active involvement of the Company's highly-renowned advisors. New hires include Dr. Nancy Sipes. Ph.D., former Director of R&D planning at Advanced Tissue Sciences, who is joining Genset as Director of Molecular and Cellular Biology, and Dr. Omid Vafa, Ph.D., a senior molecular biologist and former researcher at the Salk Institute. Dr. Joachim Fruebis, Ph.D., Director of Physiology and first author of the publication of pre-clinical studies of Famoxin, will take charge of all physiological activities in research and development.
These new scientists join the ranks of Genset's Research & Development team, now numbering over 250 researchers, including about 50 Ph.Ds. With these new hires, together with internal reassignments, Genset is well on its way to replacing the small group of researchers leaving at the end of this month. The Company has also initiated the search for a world-class scientist to head the metabolism team in San Diego, who will report to Prof. Daniel Cohen, Chief Scientific Officer.
Further, Genset announced that Professor Jerry Olefsky at the University of California at San Diego, a leading expert in the field of diabetes, and Professor Michel Darmon, from the University of Bordeaux and author of numerous works on the study of metabolic disease using animal models, will on an interim basis increase their roles as senior scientific advisors to the metabolism team in San Diego.
Professor Harvey Lodish of the Whitehead Institute for Biomedical Research, senior author on the PNAS publication detailing pre-clinical studies of gACRP30 (also known as Famoxin) and senior scientific advisor to Genset, says he looks forward to further collaboration with Genset's metabolism group. Prof. Lodish and his team discovered the full-length ACRP30 gene, of which gACRP30 is a fragment. The genetic association between the ACRP30 gene and free-fatty acid levels in obese humans was discovered by Genset's genomics group.>>> |
